Inflammatory breast carcinoma incidence and survival

Chang, Shine; Parker, Sheryl L.; Pham, Tuan H.; Buzdar, Aman U.; Hursting, Stephen D.

doi:10.1002/(sici)1097-0142(19980615)82:12<2366::aid-cncr10>3.0.co;2-n

Cited by 172 publications

(54 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both the IBC and non-IBC patients had no significant differences in previous family history of any type of breast cancer, similar to other studies in the U.S., France, and Tunisia [7,15]. Although BMI was not significantly different between IBC and non-IBC patients in this study between each countries or between the 3 countries, it is important to study it further in future studies because of the increasing incidence of overweight and obesity among women in North Africa [1,3,4].…”

Section: Discussionsupporting

confidence: 88%

Inflammatory breast cancer in North Africa: Comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco

Soliman

Kleer

Mrad

et al. 2012

View full text Add to dashboard Cite

Understanding molecular characteristics that distinguish inflammatory breast cancer (IBC) from non-IBC is crucial for elucidating breast cancer etiology and management. We included 3 sets of patients from Egypt (48 IBC and 64 non-IBC), Tunisia (24 IBC and 40 non-IBC), and Morocco (42 IBC and 41 non-IBC). Egyptian IBC patients had the highest combined erythema, edema, peau d'orange, and metastasis among the 3 IBC groups. Egyptian IBC tumors had the highest RhoC expression than Tunisians and Moroccan IBCs (87% vs. 50%, vs. 38.1, for the 3 countries, respectively). Tumor emboli were more frequent in Egyptian IBC than non-IBC (Mean ±SD: 14.1 ± 14.0 vs. 7.0 ± 12.9, respectively) (P < 0.001) and Tunisians (Mean ± SD: 3.4 ± 2.5 vs. 1.9 ± 2.0, respectively) (P < 0.01). There was no difference of emboli in Moroccan tumors (1.7 ± 1.2 vs. 1.8 ± 1.2 for IBC and non-IBC, respectively (P = 0.66). This study illustrates that RhoC overexpression and tumor emboli are more frequent in IBC relative to non-IBC from Egypt and Tunisia. Tumors of Moroccans were significantly different from Egyptian and Tunisian tumors for RhoC expression and emboli. Future studies should focus on relating epidemiologic factors and clinical pictures to molecular features of IBC in these and other populations.

show abstract

Section: Discussionsupporting

confidence: 88%

Inflammatory breast cancer in North Africa: Comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco

Soliman

Kleer

Mrad

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Even though IBC accounts for a low percentage of breast cancer cases, it accounts for 7% of all breast cancer deaths since IBC patients have poorer survival than non-IBC breast cancer patients [5,10–12]. IBC patients tend to be younger than other breast cancer patients, with a median age at diagnosis of 57 years compared to 62 for all breast cancers combined [7,8]. Diagnosis of IBC is made clinically based on diffuse erythema, edema, and fine dimpling ( peau d’orange ) [2,13].…”

Section: Introductionmentioning

confidence: 99%

Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer

Denu

Hampton

Currey

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

Purpose Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer for which treatments vary, so we sought to identify factors that affect the receipt of guideline-concordant care. Methods Patients diagnosed with IBC in 2004 were identified from the Breast and Prostate Cancer Data Quality and Patterns of Care Study, containing information from cancer registries in seven states. Variation in guideline-concordant care for IBC, based on National Comprehensive Cancer Network (NCCN) guidelines, was assessed according to patient, physician, and hospital characteristics. Results Of the 107 IBC patients in the study without distant metastasis at the time of diagnosis, only 25.8% received treatment concordant with guidelines. Predictors of non-concordance included patient age (≥70 years), non-white race, normal body mass index (BMI 18.5–25 kg/m2), patients with physicians graduating from medical school >15 years prior, and smaller hospital size (<200 beds). IBC patients survived longer if they received guideline-concordant treatment based on either 2003 (p=0.06) or 2013 (p=0.06) NCCN guidelines. Conclusions Targeting factors associated with receipt of care that is not guideline-concordant may reduce survival disparities in IBC patients. Prompt referral for neoadjuvant chemotherapy and postoperative radiation therapy is also crucial.

show abstract

“…Although a few hospital and population-based studies have examined IBC survival by patient and tumor characteristics [2, 4, 5, 7, 9–12], only one population based study examined IBC survival by socioeconomic position (SEP) and race/ethnicity [11]. This study included 935 incident cases of IBC (1998–2002) in the Florida Cancer Data System.…”

Section: Introductionmentioning

confidence: 99%

Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008

Schlichting

Soliman

Schairer

et al. 2012

Breast Cancer Res Treat

View full text Add to dashboard Cite

Although it has been previously reported that patients with inflammatory breast cancer (IBC) experience worse survival than patients with other breast cancer (BC) types, the socioeconomic and ethnic factors leading to this survival difference are not fully understood. The association between county-level percent of persons below the poverty level and BC-specific (BCS) survival for cases diagnosed from 1990 to 2008 in the Surveillance, Epidemiology, and End Results (SEER) database linked to census derived county attributes was examined. A sub-analysis of cases from 2000 to 2008 also examined BCS survival by an index combining percent below poverty and less than high school graduates as well as metropolitan versus non-metropolitan county of residence. The Kaplan–Meier estimator was used to construct survival curves by stage, inflammatory status, and county-level socioeconomic position (SEP). Stage and inflammatory status stratified proportional hazards models, adjusted for age, race/ethnicity, tumor and treatment characteristics were used to determine the hazard of BCS death by county-level SEP. Kaplan–Meier survival curves indicated IBC has worse survival than stage matched non-IBC, (stage III IBC median survival = 4.75 years vs. non-IBC = 13.4 years, p < 0.0001). Residing in a lower SEP, non-metro county significantly worsens BCS survival for non-IBC in multivariate proportional hazards models. African American cases appear to have worse survival than non-Hispanic Whites regardless of inflammatory status, stage, county-level SEP, tumor, or treatment characteristics. This is the first study to examine IBC survival by SEP in a nationwide population-based tumor registry. As this analysis found generally poorer survival for IBC, regardless of SEP or race/ethnicity, it is important that interventions that help educate women on IBC symptoms target women in various SEP and race/ethnicity groups.

show abstract

Inflammatory breast carcinoma incidence and survival

Abstract: The disparities observed in incidence trends and age at diagnosis, particularly according to race, highlight the need for further investigation of the differences between IBC and non-IBC incidence.

Cited by 172 publications

References 5 publications

Inflammatory breast cancer in North Africa: Comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco

Inflammatory breast cancer in North Africa: Comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco

Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer

Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008

Contact Info

Product

Resources

About